Monte Rosa Therapeutics
GLUE
193 hedge funds and large institutions have $2.24B invested in Monte Rosa Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 81 increasing their positions, 59 reducing their positions, and 23 closing their positions.
1,343% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $1.43M
57% more capital invested
Capital invested by funds: $1.43B → $2.24B (+$812M)
37% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 59
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
1% more funds holding
Funds holding: 191 → 193 (+2)
1.03% more ownership
Funds ownership: 108.67% → 109.69% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.5M |
| 2 |
BlackRock
New York
|
+$22.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$18.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$16.8M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$22.4M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$16.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$14.3M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$12.8M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$10.7M |
GLUE Hedge Fund Activity: Q2 2026 in Review
193 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2026, worth a combined $2.24B — up 57% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GLUE positions and 23 closed out — a net gain of 5 holders — while 81 added to existing stakes and 59 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $40.5M. The largest seller was American Century Companies, cutting an estimated $22.4M.
- 193 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2026, up from 191 in Q1 2026.
- Funds reported $2.24B of Monte Rosa Therapeutics stock for Q2 2026, up 57% quarter-over-quarter.
- 28 funds opened new Monte Rosa Therapeutics positions in Q2 2026 and 23 closed out, a net change of +5 holders.
- The largest Monte Rosa Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $40.5M added.
- The largest Monte Rosa Therapeutics seller in Q2 2026 was American Century Companies, an estimated $22.4M sold.
Based on aggregated 13F filings for Q2 2026.